title: Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
authors.forename: Fiorina
authors.initials: F
authors.lastname: Giona
authors.forename: Stefania
authors.initials: S
authors.lastname: Mariani
authors.forename: Lucio
authors.initials: L
authors.lastname: Gnessi
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Moleti
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Rea
authors.forename: Annalisa
authors.initials: A
authors.lastname: De Vellis
authors.forename: Deborah
authors.initials: D
authors.lastname: Marzella
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Testi
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism*; D002648:Child; D005260:Female; D057238:Growth Charts; D006728:Hormones / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011627:Puberty / Q000187:drug effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D015415:Biomarkers; D006728:Hormones; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate